Boston, MA, Vivakor, Inc. (OTCBB: VIVK); Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TheWallStreetLeader.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE newsletter. Please follow our thread on www.twitter.com at StockProfilerUS
Stock Profiler is pleased to introduce Vivakor, Inc. (OTCBB: VIVK) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.
-
Vivakor, Inc. closed at $0.45 Wednesday, trading 13,400 shares.
Company News- November 4, 2009: CEO of Vivakor, Inc. (OTCBB: VIVK) to Conduct Exclusive Webcast Interview with The Green Baron Report; New "Stock Pick" Coverage Initiated
Vivakor, Inc. (OTCBB: VIVK), a biomedical/biotechnology innovation company, announced yesterday that its Executive Chairman Matt Nicosia will conduct an exclusive new audio-taped webcast interview so that VIVK shareholders and the investment community can learn more about the Company's recently developments and growth plans. Unrestricted access to the webcast will be available beginning on Tuesday, November 10 at www.TheGreenBaron.com. Investors who wish to receive The Green Baron Report for free can join at http://www.thegreenbaron.com/Join.htm.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Vivakor, Inc.
Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. The R&D Core at Vivakor (the idea hub) innovates, develops and validates biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with manufacturers and niche-industry marketing and distribution leaders. Vivakor generates revenues through the licensing or sale of its technologies. Vivakor is preparing a portfolio of IP and subsidiaries. These will focus on the commercialization of technologies developed by Vivakor. More information can be found about Vivakor at www.vivakor.com.
-
Ligand Pharmaceuticals Incorporated closed at $1.66 Wednesday, trading 304,000 shares.
Company News- November 5, 2009: Ligand's JAK3 Research Collaboration Extended by Pfizer
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced earlier today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization. Under the original agreement, Ligand is entitled to receive up to $175 million in milestone payments for the successful development and commercialization of multiple products. In addition, Ligand will receive royalties on product sales.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Ligand Pharmaceuticals
Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, Pfizer and Wyeth Pharmaceuticals (now Pfizer). With nine pharmaceutical agreements and more than 20 molecules in various stages of development, Ligand utilizes proprietary technologies for identifying drugs with novel receptor and enzyme drug targets.
-
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. TheWallStreetLeader.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.markettelegraph.com, www.associatesfortune.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Market Wire, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes
((Comments on this story may be sent to info@m2.com))
